Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
DVAX Stock Chart & Stats
$15.41
-$0.11(-0.86%)
At close: 4:00 PM EST
$15.41
-$0.11(-0.86%)
Day’s Range― - ―
52-Week Range$9.20 - $15.49
Previous CloseN/A
Volume272.71K
Average Volume (3M)3.72M
Market Cap
$1.81B
Enterprise Value$996.54M
Total Cash (Recent Filing)$647.82M
Total Debt (Recent Filing)$285.02M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Feb 19, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.21
Shares Outstanding117,424,965
10 Day Avg. Volume5,102,027
30 Day Avg. Volume3,715,507
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)2.78
Price to Sales (P/S)5.99
P/FCF Ratio27.60
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit3.63
Enterprise Value/Ebitda-38.85
Forecast
1Y Price Target
$20.50Price Target Upside33.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition Strategic FitSanofi's acquisition of Dynavax complements Sanofi's vaccine capabilities and fills gaps in adult hepatitis B and shingles, supporting potential integration value upside.
Market Share And Retail AdoptionDynavax has captured near-half of the U.S. hepatitis B market and achieved majority share in retail pharmacies, indicating strong demand and potential pricing leverage.
Share RepurchaseAuthorization of a repurchase program for up to one hundred million dollars signals management confidence in cash flow and supports per-share value.
Bears Say
Deal Valuation ShortfallDeal consideration came below some analysts' net present value estimates for Heplisav, leaving potential downside for shareholders relative to prior valuations.
Licensing Financial ObligationsThe Vaxart licensing option requires significant future payments, creating financial exposure if the vaccine candidate fails to meet clinical expectations.
Rating DowngradeAn analyst downgrade to Market Perform reduces perceived momentum and may weaken investor sentiment toward the stock.
Dynavax News
DVAX FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Dynavax Technologies Corp. lowest stock price was $9.20 and its highest was $15.49 in the past 12 months.
What is Dynavax Technologies Corp.’s market cap?
Dynavax Technologies Corp.’s market cap is $1.81B.
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is Feb 19, 2026 which is in 38 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Oct 24, 2025. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.126 by $0.084.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is 0.04.
How many shares outstanding does Dynavax Technologies Corp. have?
Dynavax Technologies Corp. has 117,424,965 shares outstanding.
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of $0.21 in its last earnings report, beating expectations of $0.126. Following the earnings report the stock price went up 1.06%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Currently, no hedge funds are holding shares in DVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dynavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.50 (33.03% Upside)
$20.50 (33.03% Upside)
Blogger Sentiment
Bullish
DVAX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.10%
12-Months-Change
Fundamentals
Return on Equity
-7.14%
Trailing 12-Months
Asset Growth
-10.87%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
DVAX Stock 12 Month Forecast
Average Price Target
$20.50
▲(33.03% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Collegium Pharmaceutical
―
Ownership Overview
13.92% Insiders
14.87% Mutual Funds
27.72% Other Institutional Investors
20.06% Public Companies and
Individual Investors